Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02055170|
Recruitment Status : Terminated (Unable to improve on poor accrual to study.)
First Posted : February 5, 2014
Last Update Posted : August 31, 2018
The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. This information may be of benefit for future treatment strategies, prevention and control.
In this study, the protein where testosterone binds, called the androgen receptor (AR), will be measured in samples from the patient's biopsy and surgical tumor samples. The investigators will look at a marker of how fast the cancer is growing (Ki67) before using finasteride from your biopsy specimen. Finasteride will be taken from the day of consent until the day of the patient's surgery. This marker will be measured again after using finasteride from the surgical specimen. The investigators will be looking for a decrease in the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that this medication is blocking tumour growth.
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer||Drug: finasteride 5mg oral daily||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||March 27, 2018|
|Actual Study Completion Date :||March 27, 2018|
finasteride 5mg po od from study entry to date of surgery
Drug: finasteride 5mg oral daily
- Change in proliferation [ Time Frame: Original biopsy to surgical specimen (approx 6 weeks) ]Patients will be followed from time of consent (around the time of consultation with a Thoracic Surgeon) to date of surgery (on average, approximately 4-6 weeks following Thoracic Surgeon consultation).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02055170
|Health Sciences Centre|
|Winnipeg, Manitoba, Canada, R3A1R9|